Others

Items 7851-7900 of 13502

Page
per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Citations
  1. Drug Intermediate

    Citraconimide is a 3-methylmaleimide derivative that exhibits thiol affinity, enabling it to undergo highly regioselective reactions with various alkyl thiols. Its derivatives demonstrate growth inhibitory activity against HeLa cancer cells, making it a valuable compound in cancer research. Additionally, Citraconimide can be modified through N-substitution, halogenation, and other chemical reactions, supporting its application in the design of bioactive molecules and the development of pharmaceutical agents.
  2. Drug Impurity

    Trimetazidine impurity 6 is a chemical byproduct associated with the synthesis of Trimetazidine, a medication used primarily in the treatment of angina pectoris. This impurity serves as an important reference standard in pharmaceutical research and quality control, aiding in the assessment of Trimetazidine’s purity and safety. Its identification and analysis are crucial for ensuring compliance with regulatory standards in drug development.
  3. Drug Impurity

    Pramipexole impurity 10 is a drug impurity derived from the synthesis of Pramipexole. It is characterized as (S)-N-(2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)propionamide. This compound is relevant for quality control and regulatory compliance in pharmaceutical applications, as it provides insight into the chemical purity of Pramipexole formulations. Its analysis is essential for understanding potential side effects and ensuring drug safety in clinical settings.
  4. Drug Impurity

    Montelukast impurity 1 is a recognized impurity of the leukotriene receptor antagonist Montelukast. This compound is significant in the analysis of pharmaceutical formulations and plays a role in stability studies and quality control. Its presence can be utilized to investigate the purity and compliance of Montelukast in therapeutic applications.
  5. Drug Impurity

    Terbinafine impurity 2 is a structural impurity of the antifungal agent Terbinafine. This compound can be utilized in pharmaceutical research to assess the purity and stability of Terbinafine formulations. Its identification and characterization are essential in the development and quality control of antifungal therapies.
  6. Drug Impurity

    Amoxicillin Impurity 5 is a known impurity of the antibiotic Amoxicillin, primarily utilized for its impact on drug stability and formulation development. This compound serves as a crucial reference standard in analytical chemistry, enabling researchers to assess the purity and quality of Amoxicillin formulations. Its analysis is essential for regulatory compliance and the evaluation of pharmaceutical products.
  7. Drug Impurity

    Montelukast impurity 7 is a known impurity of the leukotriene receptor antagonist Montelukast. This compound is primarily utilized for quality control and analytical assessments in pharmaceutical research. It is essential for evaluating the purity of Montelukast in drug formulations, contributing to the understanding of its safety and efficacy profiles.
  8. Drug Impurity

    Sertraline impurity 13, also known as Sertraline ketone, is a drug impurity associated with the synthesis of Sertraline. Its presence is crucial for quality control and regulatory compliance during pharmaceutical development. This compound can be utilized in analytical studies to monitor the purity of Sertraline formulations.
  9. Drug Impurity

    Terbinafine impurity 10 is a chemical impurity associated with the antifungal agent Terbinafine. It serves as a reference standard for analytical applications, particularly in the quality control of Terbinafine formulations. This impurity is critical for ensuring the safety and efficacy of pharmaceutical products containing Terbinafine, facilitating compliance with regulatory requirements in drug development and manufacturing processes.
  10. Drug Impurity

    Roflumilast impurity 3 is a known impurity associated with Roflumilast, a selective phosphodiesterase-4 (PDE4) inhibitor. This compound serves as an analytical standard for the characterization and quantification of Roflumilast in pharmaceutical formulations. It is essential for purity assessment in drug development and quality control processes. Researchers utilize this impurity to ensure compliance with regulatory standards in drug manufacturing.
  11. Drug Impurity

    Febuxostat impurity 4 is a known impurity associated with the xanthine oxidase inhibitor, Febuxostat. It is utilized primarily in analytical chemistry for the evaluation of drug purity and quality control during formulation development. Research applications include method validation, stability testing, and assessment of potential side effects in drug metabolism studies.
  12. Drug Impurity

    Sertraline impurity 9 is a chemical impurity associated with the antidepressant sertraline. This compound serves as an essential reference standard in quality control for pharmaceutical formulations, enabling the assessment of impurity levels and ensuring product safety. Its analysis is pivotal in research related to drug development and regulatory compliance.
  13. Drug Impurity

    Solifenacin impurity 2 is a chemical impurity associated with the synthesis of Solifenacin, an antimuscarinic agent. This compound serves as a valuable standard for quality control and analytical validation in pharmaceutical research. Its identification and quantification are essential for ensuring the purity of Solifenacin formulations and for compliance with regulatory standards in drug development.
  14. Drug Impurity

    Febuxostat impurity 14 is a known impurity of the xanthine oxidase inhibitor, Febuxostat. Characterization of this impurity is essential for the evaluation of drug purity and quality control in pharmaceutical formulations. Its analysis can aid in understanding the synthesis process and potential impacts on the pharmacological profile of Febuxostat.
  15. Drug Impurity

    Apixaban impurity 31 is a drug impurity associated with the anticoagulant Apixaban. This compound is crucial for analytical chemistry studies, particularly for the identification and quantification of impurities in pharmaceutical formulations. Its use in drug development and quality control ensures the purity and safety of Apixaban-based therapeutics.
  16. Drug Impurity

    Prasugrel impurity 8 is a chemical impurity associated with the antiplatelet drug Prasugrel. This impurity serves as a critical reference standard for the quality control and characterization of pharmaceutical formulations containing Prasugrel. Its analysis is essential for ensuring the purity and safety of drug products in compliance with regulatory standards.
  17. Drug Impurity

    Quetiapine impurity 13 is a recognized impurity of the antipsychotic agent Quetiapine. This compound serves as an important reference standard in pharmaceutical research and quality control to assess the purity of Quetiapine formulations. Its characterization is crucial for ensuring the safety and efficacy of drug products in compliance with regulatory standards.
  18. Drug Impurity

    Olmesartan impurity 2, also known as N2-Tritylolmesartan medoxomil, serves as a key impurity associated with the antihypertensive agent Olmesartan. This compound is utilized primarily in pharmaceutical research and quality control to ensure the purity and stability of Olmesartan formulations. Its analysis aids in understanding the synthesis and degradation pathways of the drug, contributing to adherence to regulatory standards in drug development.
  19. Drug Impurity

    Gabapentin acid impurity 6 is a known impurity associated with Gabapentin acid. This compound is utilized primarily in the analysis of pharmaceutical formulations, ensuring the quality and safety of Gabapentin-based drugs. Its presence can be critical for researchers studying drug stability and efficacy in regulatory compliance settings.
  20. Drug Impurity

    Nimesulide impurity 5 is an impurity associated with the non-steroidal anti-inflammatory drug, Nimesulide. This compound is of interest primarily for its potential influence on the pharmacokinetics and safety profile of the parent drug. It facilitates research on drug purity and quality control, aiding in the development of safe and effective pharmaceuticals.
  21. Drug Impurity

    4-epi-Edoxaban is a known impurity of the anticoagulant Edoxaban. It plays a significant role in pharmacokinetic studies and quality control during the synthesis of Edoxaban, useful for assessing drug purity and stability. This compound is important for regulatory compliance and safety evaluations in drug development. Researchers can utilize 4-epi-Edoxaban to ensure the integrity of their Edoxaban formulations.
  22. Drug Impurity

    Fluphenazine impurity 3 is a known impurity associated with the antipsychotic drug Fluphenazine. This compound serves as a critical reference standard in the analysis and quality control of Fluphenazine formulations. Its detection and quantification assist in ensuring the purity and safety of pharmaceutical products. This reagent is essential for researchers focusing on drug development, toxicology studies, and regulatory compliance within the pharmaceutical industry.
  23. Drug Impurity

    Abiraterone impurity 15 is a chemical impurity of Abiraterone, a selective inhibitor of androgen biosynthesis. This compound is primarily utilized in quality control processes during pharmaceutical development to ensure the purity of Abiraterone formulations. Its presence in analytical studies aids in evaluating manufacturing methods and identifies potential degradation products that could impact drug efficacy and safety.
  24. Drug Impurity

    Sitagliptin impurity 17 is a known impurity of the DPP-4 inhibitor Sitagliptin, which primarily targets the enzyme dipeptidyl peptidase-4. This compound serves as a valuable analytical reference standard for research involving the purity assessment and quality control of Sitagliptin formulations. It is essential for studies focused on pharmacokinetics, metabolism, and the overall safety profile of Sitagliptin.
  25. Drug Impurity

    Dapagliflozin impurity 112 is a chemical impurity associated with the SGLT2 inhibitor Dapagliflozin. It serves as an important component for analytical and quality control studies in drug formulation. Researchers can utilize this impurity to evaluate the purity and stability of Dapagliflozin formulations, ensuring compliance with regulatory standards in pharmaceutical development.
  26. Drug Impurity

    Rifaximin impurity 6 is a chemical compound associated with Rifaximin, primarily serving as a drug impurity. It is of significant interest in pharmaceutical research for its potential implications in drug formulation and quality control. As an impurity, it aids in the comprehensive assessment of Rifaximin's purity and efficacy, contributing to the development of safer therapeutic regimens.
  27. Drug Impurity

    Trazodone impurity 14 is a chemical impurity associated with the antidepressant trazodone. It is relevant in pharmacological studies and quality control processes, useful for assessing the purity of trazodone formulations. Researchers can utilize this compound in investigations concerning drug synthesis, stability, and potential side effects, ensuring compliance with regulatory standards in pharmaceutical development.
  28. Drug Impurity

    Ramipril impurity 1, also known as Ramipril methyl ester, is an impurity associated with the angiotensin-converting enzyme inhibitor Ramipril. Its characterization is critical in the quality control and validation of pharmaceutical products containing Ramipril. This compound serves as a reference standard in drug development and analytical chemistry for assessing the purity and stability of Ramipril formulations.
  29. Drug Impurity

    Rosuvastatin impurity 9 is a known impurity of the cholesterol-lowering agent Rosuvastatin, primarily affecting its pharmacological profile. This compound is utilized primarily in the quality control and analysis of Rosuvastatin formulations to ensure compliance with regulatory standards. Its presence can offer insights into the synthesis and stability of the parent compound, making it important for pharmaceutical research and development.
  30. Drug Impurity

    Clopidogrel impurity 9 is a known impurity associated with Clopidogrel, an antiplatelet medication. It serves as a reference standard for analytical and quality control studies, assisting in the characterization and evaluation of Clopidogrel formulations. This reagent is essential for ensuring the purity and compliance of pharmaceutical products during development and regulatory assessments.
  31. Drug Impurity

    Indobufen impurity 16 is a known impurity of the anticoagulant compound Indobufen. This reagent is primarily used in pharmaceutical research and quality control to evaluate the purity and stability of Indobufen formulations. Its identification and characterization are critical for understanding the compound's safety and efficacy profiles in therapeutic applications.
  32. Drug Impurity

    Duloxetine impurity 2 is a known impurity of the antidepressant Duloxetine, which primarily acts as a selective serotonin and norepinephrine reuptake inhibitor. This compound is utilized in pharmaceutical research to assess the purity of Duloxetine formulations and to understand the potential impact of impurities on drug efficacy and safety. Its characterization is essential for quality control and regulatory compliance in the development of Duloxetine-containing products.
  33. Drug Impurity

    Fluticasone impurity 1 is a known impurity associated with Fluticasone, a corticosteroid utilized primarily for its anti-inflammatory properties. This compound plays a critical role in quality control and assurance during the synthesis and analysis of Fluticasone formulations. It is essential for researchers investigating drug purity and stability, as well as those developing analytical methods for the detection of impurities in pharmaceutical products.
  34. Drug Impurity

    Clindamycin phosphate impurity 7, also known as Lincomycin 2-phosphate, serves as a drug impurity associated with Clindamycin phosphate. Its identification is crucial for the assessment of pharmaceutical formulations and quality control processes. This compound is primarily utilized in research concerning drug stability, impurities characterization, and regulatory compliance in the pharmaceutical industry.
  35. Drug Impurity

    Tadalafil impurity 3, also known as Tadalafil impurity I, is a chemical impurity associated with Tadalafil. It is crucial for the quality control and characterization of Tadalafil in pharmaceutical formulations. Research applications include impurity profiling, stability testing, and compliance with regulatory standards in drug development.
  36. Drug Impurity

    Fluphenazine decanoate impurity 6 is a known impurity of the antipsychotic agent fluphenazine decanoate. Its characterization is essential for the quality control of fluphenazine formulations, ensuring compliance with pharmaceutical standards. Researchers may utilize this compound in studies investigating the stability and degradation pathways of fluphenazine decanoate.
  37. Drug Impurity

    Sofosbuvir Impurity 96 is a specified impurity associated with Sofosbuvir, an antiviral medication targeting the hepatitis C virus by inhibiting the NS5B polymerase. This compound serves as a critical reference standard in the analysis of Sofosbuvir formulations, ensuring quality control and compliance with pharmaceutical regulations. Its characterization is essential for laboratories conducting stability studies and impurity profiling in drug development processes.
  38. Drug Impurity

    Montelukast impurity 4 is a chemical impurity associated with Montelukast, a leukotriene receptor antagonist used primarily in the treatment of asthma and allergic rhinitis. This impurity may be crucial for pharmaceutical quality control and regulatory compliance studies, investigating the safety and efficacy of Montelukast formulations. Its characterization aids in understanding potential impacts on therapeutic outcomes and ensures the reliability of drug products containing Montelukast.
  39. Drug Impurity

    Rosuvastatin impurity 21 is a by-product of Rosuvastatin, a potent HMG-CoA reductase inhibitor. This impurity is important for analytical chemistry applications, particularly in the characterization and quality control of pharmaceutical formulations. Its identification and quantification can provide essential insights into the purity and safety of Rosuvastatin-containing products.
  40. Drug Impurity

    Dabigatran impurity 1, also known as Dabigatran Carboxamide, is a known impurity of the anticoagulant Dabigatran. This compound serves as a reference standard in quality control and analytical testing, facilitating the assessment of Dabigatran's purity and stability. Its analysis is essential for ensuring the safety and efficacy of pharmaceutical formulations containing Dabigatran.
  41. Drug Impurity

    Citalopram Impurity 3 Hydrobromide is a known impurity of the selective serotonin reuptake inhibitor Citalopram. This compound is utilized primarily in research settings to assess the purity and quality control of pharmaceutical formulations. Its presence can inform studies on drug stability and regulatory compliance in drug development processes.
  42. Drug Impurity

    rel-trans-Ketoconazole is a drug impurity with relevance in pharmacological research. It serves as a crucial reference standard for the analytical characterization of ketoconazole formulations and related compounds. Its study aids in understanding the stability, safety, and efficacy profiles of ketoconazole derivatives in various biological systems.
  43. Drug Impurity

    Salbutamol impurity 6 is a chemical compound associated with the drug impurity profile of salbutamol. It serves as a reference standard in the analysis and characterization of pharmaceutical formulations, aiding in the assessment of product quality and safety. This impurity can be utilized in research focused on drug metabolism and the development of analytical methods for detecting impurities in pharmaceutical products.
  44. Drug Intermediate

    3'-Fluoro-4'-methylacetanilide serves as a critical drug intermediate in the synthesis of various active pharmaceutical compounds. This compound exhibits properties that facilitate the development of biologically active molecules, making it valuable in medicinal chemistry and pharmaceutical research. Its utility in the preparation of targeted therapeutics underscores its importance in drug discovery and development processes.
  45. Drug Intermediate

    2-Acetamidopyridine serves as a crucial drug intermediate in the synthesis of diverse active pharmaceutical ingredients. Its structural properties facilitate the formation of various biologically active compounds, making it valuable in medicinal chemistry and drug development. This reagent is utilized in research applications that explore new therapeutic agents and optimize chemical pathways.
  46. Drug Impurity

    Mesalazine impurity 8 is a known impurity of Mesalazine, a 5-aminosalicylic acid derivative used primarily in the treatment of inflammatory bowel diseases. This compound serves as an important analytical standard for assessing the purity of Mesalazine formulations. Its presence and quantification are essential for ensuring the quality and safety of pharmaceutical products containing Mesalazine.
  47. Drug Impurity

    Benzaldehyde dimethyl acetal serves as a chemical reagent commonly identified as a drug impurity. This compound can impact the purity and safety profile of pharmaceutical formulations, making its analysis critical in drug development and quality control studies. It is utilized in researching stability, interactions, and the degradation pathways of various drug substances.
  48. Drug Intermediate

    (S)-3-Amino-2,2-dimethyl-4-oxoazetidin-1-yl hydrogen sulfate serves as a versatile drug intermediate, facilitating the synthesis of diverse active pharmaceutical compounds. Its unique structural features make it valuable in pharmaceutical research and development, particularly in designing new therapeutic agents. This compound is instrumental in exploring novel drug formulations and enhancing medicinal chemistry efforts.
  49. Drug Intermediate

    (2R,4S)-Ethyl 5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpentanoate acts as a key drug intermediate in the synthesis of diverse bioactive compounds. This reagent is integral for researchers working in medicinal chemistry, facilitating the development of new therapeutic agents. Its structure supports various modifications, enabling the exploration of pharmacological properties and mechanisms of action in drug design.
  50. Drug Impurity

    Camptothecin impurity 1 is a structural variant associated with Camptothecin, an anticancer compound. This impurity may influence the pharmacological properties of Camptothecin and is relevant in the study of drug formulation and stability. Its characterization is crucial for quality control in research applications focused on cancer therapy and drug development.

Items 7851-7900 of 13502

Page
per page
Set Descending Direction